华东医药去年营收增长3.16%至419.06亿元，以“半日达”为标准布局煎药中心

Core Insights - The company reported a total revenue of approximately 41.91 billion yuan in 2024, representing a year-on-year increase of 3.16% compared to 40.62 billion yuan in 2023 [1] - The pharmaceutical industry is experiencing significant growth driven by the introduction of new products into the medical insurance catalog, with notable sales increases in innovative drugs and biosimilars [3] - The company has established a strong market presence in specialized chronic disease treatment areas, maintaining a leading market share in various therapeutic fields [3] Revenue Breakdown - Total revenue for 2024 was 41.91 billion yuan, with the commercial sector contributing 28.47 billion yuan (67.94% of total revenue), and the manufacturing sector contributing 15.78 billion yuan (37.65% of total revenue) [1] - The medical beauty business generated 2.33 billion yuan, showing a decline of 4.94% from the previous year [1][8] - Internal sales accounted for 97.39% of total revenue, while external sales made up 2.61%, with external sales decreasing by 23.29% year-on-year [1] Product and Market Development - The company has a comprehensive pipeline of over 20 products in the diabetes treatment sector, covering various clinical mainstream targets [4] - In the field of autoimmune diseases, the company has over 20 products in development, with a focus on a wide range of conditions [4] - The medical beauty segment is expected to stabilize and grow, with the company actively expanding its global market presence through subsidiaries [8] Financial Performance - The core subsidiary, China Medical East, achieved sales revenue of 13.81 billion yuan, a year-on-year increase of 13.05%, and a net profit of 2.88 billion yuan, up 29.04% [5] - The pharmaceutical commercial segment reported revenue of 27.09 billion yuan, a slight increase of 0.41%, with a net profit of 456 million yuan, up 5.58% [7] - The industrial microbiology segment saw a significant revenue increase of 43.12%, with various sub-segments experiencing substantial growth [8]